SCHEMBL6608142

SCHEMBL6608142

CC(c1ccccn1)S([O])(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
SLC6A3 Q01959 2/20 0.44
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
TSHR P16473 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
KCNA5 P22460 5/20 0.41
KDM4E B2RXH2 3/20 0.41
PKM P14618 1/20 0.41
KCNH2 Q12809 1/20 0.41
ALDH1A1 P00352 1/20 0.40
NFE2L2 Q16236 2/20 0.40
KCNE1 P15382 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP2D6 P10635 1/20 0.39
ABCB11 O95342 1/20 0.38
LMNA P02545 1/20 0.38
ESR1 P03372 1/20 0.38
ADRA2A P08913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL9065487 0.85 CYP1A2 (0.42) CYP1A2CYP3A4SLC6A3SLC6A2SLC6A4
SCHEMBL30042788 0.82 CYP3A4 (0.44) CYP1A2CYP3A4SLC6A3SLC6A2SLC6A4
SCHEMBL7335217 0.82 CYP1A2 (0.44) CYP1A2CYP3A4SLC6A3SLC6A2SLC6A4
SCHEMBL4807002 0.82 CYP1A2 (0.47) CYP1A2CYP3A4SLC6A3SLC6A2SLC6A4
SCHEMBL15668216 0.82 CYP3A4 (0.44) CYP1A2CYP3A4SLC6A3SLC6A2SLC6A4
SCHEMBL11551880 0.81 CYP1A2 (0.46) CYP1A2CYP3A4SLC6A3SLC6A2SLC6A4
SCHEMBL15550675 0.79 CYP1A2 (0.41) CYP1A2CYP3A4SLC6A3SLC6A2SLC6A4
SCHEMBL2375133 0.74 KDM4E (0.50) CYP1A2CYP3A4SLC6A3SLC6A2SLC6A4
SCHEMBL17603147 0.74
SCHEMBL243460 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1073428-B1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES CHOONGWAE PHARMA CO LTD (KR) 2004-10-27 EP claimed
EP-1073428-B1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES CHOONGWAE PHARMA CO LTD (KR) 2004-10-27 EP disclosed
US-6693126-B2 OXIME-SUBSTITUTED M-DIHYDROXYBENZENE OR 1,3-BENZODIOXOLE COMPOUND OF GIVEN FORMULA AND AN INERT CARRIER CHOONGWAE PHARM. CO., LTD. (KR) 2004-02-17 US disclosed
US-20030083326-A1 Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases CHOONGWAE PHARM. CO., LTD. (KR) 2003-05-01 US disclosed
EP-1073428-A1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES Choongwae Pharma Co., Ltd. (KR) 2001-02-07 EP disclosed
WO-1999055318-A1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES CHOONGWAE PHARM. CO., LTD. (KR) 1999-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083326-A1 Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases SLC10A1, SLC10A2, ABCB11 CYP1A2 113/4885CYP3A4 287/4885SLC6A3 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.